Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 19/20 | 0.82 |
| ▸ | FLT1 | P17948 | 5/20 | 0.82 |
| ▸ | FLT4 | P35916 | 5/20 | 0.82 |
| ▸ | RET | P07949 | 2/20 | 0.79 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.79 |
| ▸ | KIT | P10721 | 2/20 | 0.79 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.53 |
| ▸ | TNNI3K | Q59H18 | 3/20 | 0.53 |
| ▸ | BRAF | P15056 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1875364 | 0.90 | KDR (0.80) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2434062 | 0.90 | KDR (1.00) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2435271 | 0.89 | KDR (0.85) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2433502 | 0.89 | KDR (0.80) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2434594 | 0.88 | KDR (1.00) | KDRFLT1FLT4RETPDGFRB | |
| Bfh-772 SCHEMBL29366190 | 0.88 | KDR (1.00) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2434509 | 0.88 | KDR (0.81) | KDRFLT1FLT4RETPDGFRB | |
| Bfh-772 SCHEMBL987715 | 0.88 | KDR (1.00) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2437718 | 0.88 | KDR (0.80) | KDRFLT1FLT4RETPDGFRB | |
| Bfh-772 SCHEMBL1041162 | 0.88 | KDR (0.98) | KDRFLT1FLT4RETPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026247-B2 | Bicyclic amides as kinase inhibitors | NOVARTIS AG (CH) | 2011-09-27 | — | — | US | disclosed |
| US-20110112121-A1 | Pharmaceutical Compositions and Solid Forms | NOVARTIS AG (CH) | 2011-05-12 | — | — | US | disclosed |
| WO-2011003858-A2 | PHARMACEUTICAL COMPOSITIONS AND SOLID FORMS | NOVARTIS AG (CH) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112121-A1 | Pharmaceutical Compositions and Solid Forms | VEGFA, FLT1, FLT4 | KDR 4/4885FLT1 2/4885FLT4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.